ArticleScientific reports2026

Cost-effectiveness of cabozantinib versus placebo for advanced neuroendocrine tumors from crossover-adjusted analysis in the United States and China.

Wenwang Lang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.